Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Form 144 notice for Cencora, Inc. (COR) records a proposed sale of 31,350 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $9,140,092.50 and an approximate sale date of 09/16/2025. The filing breaks the lot into 2,000 shares acquired on 09/30/2023 by restricted stock vesting (compensation) and 29,350 shares tied to options granted on 11/13/2019 with a payment date of 09/16/2025 identified as cash.
The form also lists three recent insider sales by Steven Collis: 14,579 shares on 06/24/2025 for $4,266,106.98, 14,578 shares on 07/22/2025 for $4,266,543.26, and 14,579 shares on 08/19/2025 for $4,227,618.42. The notice includes the mandatory representation that the seller is not aware of undisclosed material adverse information.
Cencora, Inc. filed a Form 8-K reporting entry into material agreements. The company executed Amendment No. 2 to the Term Credit Agreement dated September 5, 2025, among the company, the lenders party thereto, and Bank of America, N.A. as administrative agent. On the same date it executed Amendment No. 2 to an Uncommitted Money Market Line Credit Agreement dated September 5, 2025, between the company and Société Générale, New York Branch as lender. The filing references the company's common stock (NYSE: COR), two series of senior notes (2.875% due 2028 and 3.625% due 2032), and certain solicitation and pre-commencement communication rules. The cover page interactive data file is embedded within the Inline XBRL document.
Cencora, Inc. reported that it has reached an agreement, subject to court approval, to resolve a stockholder derivative lawsuit in the Delaware Court of Chancery. The case, brought by Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan, alleges breaches of fiduciary duty related to oversight of the company’s controlled substance diversion control programs.
Under a Stipulation and Agreement of Settlement filed on August 15, 2025, insurance carriers would pay the company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to the plaintiffs’ counsel, if the Court approves the settlement. The defendants do not admit liability and expressly deny any wrongdoing. The Court has entered a scheduling order and directed the company to file this report, attach the settlement documents, and post them in its investor relations website.
Cencora, Inc. announced that its Board of Directors has appointed D. Mark Durcan as Chairman of the Board, effective October 1, 2025. Durcan has been a director since September 2015 and has served as Lead Independent Director since March 2023, so this move elevates an experienced, long‑tenured board member to the chair role.
Durcan will succeed Steven H. Collis, who, as previously reported, will retire as Executive Chairman and as a director at the end of Cencora’s fiscal year ending September 30, 2025. When Collis steps down, the size of the Board will decrease from 11 to 10 directors. The company states that Collis’ decision to retire is not due to any disagreement regarding its operations, policies, or practices.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported option exercise and open-market sales on 08/19/2025. He exercised 12,579 non-qualified stock options with an exercise price of $86.09, acquiring 12,579 shares underlying those options. The exercise increased his direct holdings to 322,491.665 shares. On the same date he sold 14,579 shares at $289.98 per share, leaving 307,912.665 shares after the transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on 11/25/2024. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercises and open-market sales on 08/18/2025. He exercised 3,225 non-qualified stock options with an exercise price of $86.09 under a grant that vests in four prior annual installments, and those options produced 3,225 shares recorded as acquired. The same day he sold 4,968 shares at $293.53 per share pursuant to a Rule 10b5-1 trading plan adopted 11/15/2024. After these transactions he beneficially owned 40,608 shares and held 22,577 derivative securities (options) reported as direct ownership.
Cencora, Inc. (COR) Form 144 shows proposed and recent insider sales of common stock by Steven Collis. The filing notifies a brokered proposed sale of 14,579 shares with an aggregate market value of $4,227,618.42 scheduled for 08/19/2025 on the NYSE through Fidelity Brokerage Services. The filing also discloses the acquisition history for the shares to be sold: 2,000 shares from restricted stock vesting on 09/30/2023 (compensation) and 12,579 shares from an option exercise dated 08/19/2025 (cash).
Separately, three insider sales by Steven Collis during the past three months are reported: 14,578 shares on 05/20/2025 for $4,283,599.52, 14,579 shares on 06/24/2025 for $4,266,106.98, and 14,578 shares on 07/22/2025 for $4,265,100.54. The filing includes the seller's representation about lack of undisclosed material information and a signature notice regarding legal penalties for misstatement.
Cencora, Inc. insider sale notice under Rule 144: The filing shows a proposed sale of 4,968 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $1,458,257.04 and an approximate sale date of 08/18/2025. The shares were acquired partly through restricted stock vesting on 09/30/2023 (1,743 shares) as compensation and partly via option exercise on 08/18/2025 (3,225 shares) related to an option granted 11/13/2019 and paid in cash. The filer also disclosed three prior monthly sales of similar sizes in May, June and July 2025 totaling 14,906 shares with gross proceeds of approximately $4.38 million. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Q3 FY25 results: Revenue rose 8.7 % YoY to $80.7 B; gross profit +20 % to $2.9 B; operating income +29 % to $867.7 M; diluted EPS climbed 45 % to $3.52. For the nine-month period, sales reached $237.6 B (+10.6 %) and net income was $1.89 B (+25.8 %).
Cash & liquidity: Operating cash flow dropped to $0.74 B (vs $2.48 B last year) as working-capital swings outweighed earnings growth. Cash & equivalents fell to $2.23 B.
Major transaction: Closed the $5.7 B acquisition of 85 % of Retina Consultants of America, adding $1.4 B revenue and $4.8 B goodwill. Financing included $4.5 B USD notes, €1.0 B notes and a $1.5 B term loan, lifting long-term debt to $8.0 B (from $3.8 B).
Balance sheet: Total assets $74.0 B; goodwill $14.3 B. Accrued opioid-related litigation liability steady at $4.28 B. Share buy-backs of $435 M reduced outstanding shares to 193.9 M.
Segments: U.S. Healthcare Solutions delivered $72.9 B revenue (+8.5 %); International $7.79 B (+10.5 %). FX gains drove $367 M other comprehensive income.
Key watch-points: leverage expansion, potential PharmaLex goodwill impairment ($724 M), rising interest expense and continuing opioid/DEA litigation.